Download PDF
Horm Metab Res 2016; 48(11): 755-763
DOI: 10.1055/s-0042-110571
Review
© Georg Thieme Verlag KG Stuttgart · New York

Glucocorticoid Signaling and Bone Biology

T. Komori
1   Department of Cell Biology, Unit of Basic Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
› Author Affiliations
Further Information

Publication History

received 11 April 2016

accepted 08 June 2016

Publication Date:
21 November 2016 (online)

Also available at
   Permissions and Reprints

Abstract

Since glucocorticoids remain an effective therapeutic option for the treatment of many inflammatory and autoimmune diseases, glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis. Fractures may occur in as many as 30–50% of patients receiving chronic glucocorticoid therapy. Under physiological conditions, glucocorticoids are required for normal bone development due to their regulation of osteoblast differentiation, possibly via the Wnt/β-catenin pathway and TSC22D3. However, serum levels of endogenous corticosterone are elevated in aged mice and glucocorticoids exert negative effects on the survival of osteoblasts and osteocytes as well as angiogenesis. Glucocorticoid treatments impair bone formation and enhance bone resorption. Excess glucocorticoids induce osteoblast and osteocyte apoptosis by increasing pro-apoptotic molecules, reactive oxygen species, and endoplasmic reticulum stress and suppressing the Wnt/β-catenin pathway. Autophagy protects osteocytes from glucocorticoid-induced apoptosis, but passed some threshold, the process of autophagy leads the cells to apoptosis. Excess glucocorticoids impair osteoblastogenesis by inducing Wnt antagonists, including Dkk1, Sost, and sFRP-1. However, the findings are controversial and the involvement of Wnt antagonists requires further study. Excess glucocorticoids reduce the phosphorylation of Akt and GSK3β, which enhances the degradation of β-catenin. Excess glucocorticoids have been shown to modulate the expression of miRNAs, including miR-29a, miR-34a-5p, and miR-199a-5p, which regulate the proliferation and differentiation of osteoblast lineage cells. Excess glucocorticoids also enhance bone resorption by reducing OPG expression, increasing Rankl expression and reactive oxygen species, and prolonging the life span of osteoclasts; however, they also suppress the bone-degrading capacity of osteoclasts by disturbing the organization of the cytoskeleton.

Key words

apoptosis - autophagy - wnt - osteoblast - osteoclast - OPG
 

  • References

  • 1 Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-1328
    CrossrefPubMedGoogle Scholar
  • 2 Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008; 58: 1674-1686
    CrossrefPubMedGoogle Scholar
  • 3 Komori T. Animal models for osteoporosis. Eur J Pharmacol 2015; 759: 287-294
    CrossrefPubMedGoogle Scholar
  • 4 Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol 2007; 275: 13-29
    CrossrefPubMedGoogle Scholar
  • 5 Sher LB, Woitge HW, Adams DJ, Gronowicz GA, Krozowski Z, Harrison JR, Kream BE. Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology 2004; 145: 922-929
    CrossrefPubMedGoogle Scholar
  • 6 Sher LB, Harrison JR, Adams DJ, Kream BE. Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif Tissue Int 2006; 79: 118-125
    CrossrefPubMedGoogle Scholar
  • 7 Zhou H, Mak W, Kalak R, Street J, Fong-Yee C, Zheng Y, Dunstan CR, Seibel MJ. Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development 2009; 136: 427-436
    CrossrefPubMedGoogle Scholar
  • 8 Kalak R, Zhou H, Street J, Day RE, Modzelewski JR, Spies CM, Liu PY, Li G, Dunstan CR, Seibel MJ. Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice. Bone 2009; 45: 61-67
    CrossrefPubMedGoogle Scholar
  • 9 Yang M, Trettel LB, Adams DJ, Harrison JR, Canalis E, Kream BE. Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation. Bone 2010; 47: 573-582
    CrossrefPubMedGoogle Scholar
  • 10 Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schutz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 1995; 9: 1608-1621
    CrossrefPubMedGoogle Scholar
  • 11 Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, Kirilov M, Mandic V, Takacz A, Schmidt-Ullrich R, Ostermay S, Schinke T, Spanbroek R, Zaiss MM, Angel PE, Lerner UH, David JP, Reichardt HM, Amling M, Schutz G, Tuckermann JP. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010; 11: 517-531
    CrossrefPubMedGoogle Scholar
  • 12 O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835-1841
    CrossrefPubMedGoogle Scholar
  • 13 Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O’Brien CA, Thostenson J, Roberson PK, Boskey AL, Clemens TL, Manolagas SC. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010; 9: 147-161
    CrossrefPubMedGoogle Scholar
  • 14 Jia D, O’Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006; 147: 5592-5599
    CrossrefPubMedGoogle Scholar
  • 15 Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006; 116: 2152-2160
    CrossrefPubMedGoogle Scholar
  • 16 Pan G, Cao J, Yang N, Ding K, Fan C, Xiong WC, Hamrick M, Isales CM, Shi XM. Role of glucocorticoid-induced leucine zipper (GILZ) in bone acquisition. J Biol Chem 2014; 289: 19373-19382
    CrossrefPubMedGoogle Scholar
  • 17 Wang HL, Yang CH, Lee HH, Kuo JC, Hur SS, Chien S, Lee OK, Hung SC, Chang ZF. Dexamethasone-induced cellular tension requires a SGK1-stimulated Sec5-GEF-H1 interaction. J Cell Sci 2015; 128: 3757-3768
    CrossrefPubMedGoogle Scholar
  • 18 Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274-282
    CrossrefPubMedGoogle Scholar
  • 19 Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999; 104: 1363-1374
    PubMedGoogle Scholar
  • 20 Espina B, Liang M, Russell RG, Hulley PA. Regulation of bim in glucocorticoid-mediated osteoblast apoptosis. J Cell Physiol 2008; 215: 488-496
    CrossrefPubMedGoogle Scholar
  • 21 Chang JK, Li CJ, Liao HJ, Wang CK, Wang GJ, Ho ML. Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts. Toxicology 2009; 258: 148-156
    CrossrefPubMedGoogle Scholar
  • 22 Chen F, Zhang L, OuYang Y, Guan H, Liu Q, Ni B. Glucocorticoid induced osteoblast apoptosis by increasing E4BP4 expression via up-regulation of Bim. Calcif Tissue Int 2014; 94: 640-647
    CrossrefPubMedGoogle Scholar
  • 23 Li H, Qian W, Weng X, Wu Z, Zhuang Q, Feng B, Bian Y. Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells. PLoS One 2012; 7: e37030
    CrossrefPubMedGoogle Scholar
  • 24 Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J Biol Chem 2007; 282: 24120-24130
    CrossrefPubMedGoogle Scholar
  • 25 Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem 2011; 286: 44326-44335
    CrossrefPubMedGoogle Scholar
  • 26 Kitase Y, Lee S, Gluhak-Heinrich J, Johnson ML, Harris SE, Bonewald LF. CCL7 is a protective factor secreted by mechanically loaded osteocytes. J Dent Res 2014; 93: 1108-1115
    CrossrefPubMedGoogle Scholar
  • 27 Sato AY, Tu X, McAndrews KA, Plotkin LI, Bellido T. Prevention of glucocorticoid induced-apoptosis of osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo in female mice. Bone 2015; 73: 60-68
    CrossrefPubMedGoogle Scholar
  • 28 Xia X, Kar R, Gluhak-Heinrich J, Yao W, Lane NE, Bonewald LF, Biswas SK, Lo WK, Jiang JX.. Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res 2010; 25: 2479-2488
    CrossrefPubMedGoogle Scholar
  • 29 Jia J, Yao W, Guan M, Dai W, Shahnazari M, Kar R, Bonewald L, Jiang JX, Lane NE. Glucocorticoid dose determines osteocyte cell fate. FASEB J 2011; 25: 3366-3376
    CrossrefPubMedGoogle Scholar
  • 30 Piemontese M, Onal M, Xiong J, Wang Y, Almeida M, Thostenson JD, Weinstein RS, Manolagas SC, O’Brien CA. Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone. Bone 2015; 75: 18-26
    CrossrefPubMedGoogle Scholar
  • 31 Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2004; 318: 259-264
    CrossrefPubMedGoogle Scholar
  • 32 Hurson CJ, Butler JS, Keating DT, Murray DW, Sadlier DM, O'Byrne JM, Doran PP. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet Disord 2007; 8: 12
    CrossrefPubMedGoogle Scholar
  • 33 Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008; 149: 1793-1801
    CrossrefPubMedGoogle Scholar
  • 34 Butler JS, Queally JM, Devitt BM, Murray DW, Doran PP, O’Byrne JM. Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord 2010; 11: 210
    CrossrefPubMedGoogle Scholar
  • 35 Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2009; 379: 261-266
    CrossrefPubMedGoogle Scholar
  • 36 Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, Rauner M. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res 2012; 27: 2242-2250
    CrossrefPubMedGoogle Scholar
  • 37 Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T. Protection from Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. J Bone Miner Res. 2016 DOI: 10.1002/jbmr.2869
    PubMedGoogle Scholar
  • 38 Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 2013; 57: 272-276
    CrossrefPubMedGoogle Scholar
  • 39 Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 2009; 85: 538-545
    CrossrefPubMedGoogle Scholar
  • 40 Wang FS, Ko JY, Weng LH, Yeh DW, Ke HJ, Wu SL. Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss. Life Sci 2009; 85: 685-692
    CrossrefPubMedGoogle Scholar
  • 41 Smith E, Frenkel B. Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and -independent manner. J Biol Chem 2005; 280: 2388-2394
    CrossrefPubMedGoogle Scholar
  • 42 Rokutanda S, Fujita T, Kanatani N, Yoshida CA, Komori H, Liu W, Mizuno A, Komori T. Akt regulates skeletal development through GSK3, mTOR, and FoxOs. Dev Biol 2009; 328: 78-93
    CrossrefPubMedGoogle Scholar
  • 43 Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, Capeau J. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001; 20: 252-259
    CrossrefPubMedGoogle Scholar
  • 44 Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH, Matsui T, Rosenzweig A, Taylor WG, Rubin JS, Perrella MA, Lee ME. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 2001; 276: 17479-17483
    CrossrefPubMedGoogle Scholar
  • 45 Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 2000; 275: 32475-32481
    CrossrefPubMedGoogle Scholar
  • 46 McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, Alessi DR. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 2005; 24: 1571-1583
    CrossrefPubMedGoogle Scholar
  • 47 Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJ, Maurice MM, Mahmoudi T, Clevers H. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 2012; 149: 1245-1256
    CrossrefPubMedGoogle Scholar
  • 48 Naito M, Omoteyama K, Mikami Y, Takahashi T, Takagi M. Inhibition of Wnt/beta-catenin signaling by dexamethasone promotes adipocyte differentiation in mesenchymal progenitor cells, ROB-C26. Histochem Cell Biol 2012; 138: 833-845
    CrossrefPubMedGoogle Scholar
  • 49 Li J, Zhang N, Huang X, Xu J, Fernandes JC, Dai K, Zhang X. Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C/EBPalpha promoter methylation. Cell Death Dis 2013; 4: e832
    CrossrefPubMedGoogle Scholar
  • 50 Wang FS, Chuang PC, Lin CL, Chen MW, Ke HJ, Chang YH, Chen YS, Wu SL, Ko JY. MicroRNA-29a protects against glucocorticoid-induced bone loss and fragility in rats by orchestrating bone acquisition and resorption. Arthritis Rheum 2013; 65: 1530-1540
    CrossrefPubMedGoogle Scholar
  • 51 Ko JY, Chuang PC, Chen MW, Ke HC, Wu SL, Chang YH, Chen YS, Wang FS. MicroRNA-29a ameliorates glucocorticoid-induced suppression of osteoblast differentiation by regulating beta-catenin acetylation. Bone 2013; 57: 468-475
    CrossrefPubMedGoogle Scholar
  • 52 Kang H, Chen H, Huang P, Qi J, Qian N, Deng L, Guo L. Glucocorticoids impair bone formation of bone marrow stromal stem cells by reciprocally regulating microRNA-34a-5p. Osteoporos Int 2016; 27: 1493-1505
    CrossrefPubMedGoogle Scholar
  • 53 Shi C, Huang P, Kang H, Hu B, Qi J, Jiang M, Zhou H, Guo L, Deng L. Glucocorticoid inhibits cell proliferation in differentiating osteoblasts by microRNA-199a targeting of WNT signaling. J Mol Endocrinol 2015; 54: 325-337
    CrossrefPubMedGoogle Scholar
  • 54 Shen C, Kim MR, Noh JM, Kim SJ, Ka SO, Kim JH, Park BH, Park JH. Glucocorticoid Suppresses Connexin 43 Expression by Inhibiting the Akt/mTOR Signaling Pathway in Osteoblasts. Calcif Tissue Int 2016; 99: 88-97
    CrossrefPubMedGoogle Scholar
  • 55 Koromila T, Baniwal SK, Song YS, Martin A, Xiong J, Frenkel B. Glucocorticoids antagonize RUNX2 during osteoblast differentiation in cultures of ST2 pluripotent mesenchymal cells. J Cell Biochem 2014; 115: 27-33
    CrossrefPubMedGoogle Scholar
  • 56 Jensen PR, Andersen TL, Hauge EM, Bollerslev J, Delaisse JM. A joined role of canopy and reversal cells in bone remodeling – lessons from glucocorticoid-induced osteoporosis. Bone 2015; 73: 16-23
    CrossrefPubMedGoogle Scholar
  • 57 Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004; 89: 4923-4928
    CrossrefPubMedGoogle Scholar
  • 58 Brabnikova Maresova K, Pavelka K, Stepan JJ. Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int 2013; 92: 354-361
    CrossrefPubMedGoogle Scholar
  • 59 Hirayama T, Sabokbar A, Athanasou NA. Effect of corticosteroids on human osteoclast formation and activity. J Endocrinol 2002; 175: 155-163
    CrossrefPubMedGoogle Scholar
  • 60 Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 2005; 20: 390-398
    CrossrefPubMedGoogle Scholar
  • 61 Shi J, Wang L, Zhang H, Jie Q, Li X, Shi Q, Huang Q, Gao B, Han Y, Guo K, Liu J, Yang L, Luo Z. Glucocorticoids: Dose-related effects on osteoclast formation and function via reactive oxygen species and autophagy. Bone 2015; 79: 222-232
    CrossrefPubMedGoogle Scholar
  • 62 Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357
    CrossrefPubMedGoogle Scholar
  • 63 Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-4389
    CrossrefPubMedGoogle Scholar
  • 64 Humphrey EL, Williams JH, Davie MW, Marshall MJ. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006; 38: 652-661
    CrossrefPubMedGoogle Scholar
  • 65 Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 2008; 103: 335-345
    CrossrefPubMedGoogle Scholar
  • 66 Shi C, Qi J, Huang P, Jiang M, Zhou Q, Zhou H, Kang H, Qian N, Yang Q, Guo L, Deng L. MicroRNA-17/20a inhibits glucocorticoid-induced osteoclast differentiation and function through targeting RANKL expression in osteoblast cells. Bone 2014; 68: 67-75
    CrossrefPubMedGoogle Scholar
  • 67 Moriishi T, Fukuyama R, Ito M, Miyazaki T, Maeno T, Kawai Y, Komori H, Komori T. Osteocyte network; a negative regulatory system for bone mass augmented by the induction of rankl in osteoblasts and sost in osteocytes at unloading. PLoS One 2012; 7: e40143
    CrossrefPubMedGoogle Scholar
  • 68 Komori T. Functions of the osteocyte network in the regulation of bone mass. Cell Tissue Res 2013; 352: 191-198
    CrossrefPubMedGoogle Scholar
  • 69 Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109: 1041-1048
    CrossrefPubMedGoogle Scholar
  • 70 Lin NY, Chen CW, Kagwiria R, Liang R, Beyer C, Distler A, Luther J, Engelke K, Schett G, Distler JH. Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. Ann Rheum Dis 2016; 75: 1203-1210
    CrossrefPubMedGoogle Scholar
  • 71 Hong JM, Teitelbaum SL, Kim TH, Ross FP, Kim SY, Kim HJ. Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation. J Bone Miner Res 2011; 26: 657-665
    CrossrefPubMedGoogle Scholar
  • 72 Soe K, Delaisse JM. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J Bone Miner Res 2010; 25: 2184-2192
    CrossrefPubMedGoogle Scholar